Inozyme Pharma, Inc.
INZY · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.22 | -0.16 | 0.30 | -0.16 |
| FCF Yield | -49.83% | -11.04% | -7.42% | -8.66% |
| EV / EBITDA | -3.01 | -7.84 | -15.38 | -11.97 |
| Quality | ||||
| ROIC | -35.16% | -25.95% | -19.03% | -19.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.04 | 0.71 | 1.00 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -51.78% | 21.74% | -3.73% | 3.69% |
| Safety | ||||
| Net Debt / EBITDA | -0.80 | -1.01 | -0.97 | -1.24 |
| Interest Coverage | -19.69 | -19.11 | -17.55 | -19.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |